SnowWorld N.V.

Regulatory Filings • Mar 30, 2011

P R E S S R E L E A S E

Lelystad, the Netherlands, 30 March 2011

FORNIX SHAREHOLDERS APPROVE SALE OF LAPROLAN

At the Extraordinary Annual General Meeting of Shareholders of Fornix BioSciences N.V. held today in Lelystad, the Netherlands, the shareholders have approved the previously announced sale (effective 1 January 2011) of Fornix' Medical Aid Division (Laprolan) to Rochester Medical Corporation (the Transaction).

For more information about the Transaction we refer to the press release of Fornix published on 15 February 2011 as well as the shareholder circular published on the same date. Fornix and Rochester Medical Corporation expect to complete the Transaction by 13 April 2011 at the latest; that is to say, the transfer of ownership of all outstanding shares in the capital of Laprolan B.V. to Rochester Medical Corporation upon payment of the purchase price.

E N D O F P R E S S R E L E A S E

For additional information, please contact: Fornix BioSciences N.V. C.L. Bergman, CEO Tel. +31 (0) 320) 26 77 99

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) which was engaged in the distribution of medical aids and medical and nursing consumables.

The company, which operates sites in Lelystad and Beuningen, currently employs approximately 23 people. Fornix BioSciences N.V. operates mainly in the Netherlands and is currently only engaged in the sale and distribution of medical aids. The Medical Aids Division consists of Laprolan B.V., which is located in Beuningen, and specialises in the sale, marketing and distribution in the Netherlands of a wide range of medical aids and medical and nursing consumables.

Following the transfer of all of its shares in Laprolan B.V. to Rochester Medical Corporation, which will take place in the very near future, Fornix BioSciences N.V.'s will have divested all of its activities.